Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NAVB Navidea Biopharmaceuticals	$0.00	$0.00	$0.00 ▼ $0.13	$50K	1.71	7,603 shs	35 shs
NCNA NuCana	$3.44 +3.9%	$11.25	$3.05 ▼ $1,650.00	$100K	1.4	848,419 shs	416,279 shs
SMFL Smart for Life	$0.00 -69.4%	$0.01	$0.00 ▼ $1.56	$23K	17.05	6,340 shs	1,949 shs
SYRS Syros Pharmaceuticals	$0.02 +1,143.8%	$0.01	$0.00 ▼ $0.10	$534K	1.31	186,243 shs	4,661 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NAVB Navidea Biopharmaceuticals	0.00%	0.00%	0.00%	-28.57%	-50.00%
NCNA NuCana	+3.93%	-7.77%	-67.30%	-54.74%	-99.80%
SMFL Smart for Life	-69.44%	-46.77%	-91.75%	+32.00%	-99.79%
SYRS Syros Pharmaceuticals	+1,143.75%	+1,143.75%	+2.05%	-36.01%	-98.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	3.4349 of 5 stars	3.3	4.0	0.0	0.0	2.6	2.5	1.3
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	3.5914 of 5 stars	3.0	5.0	0.0	4.3	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NAVB Navidea Biopharmaceuticals	0.00	N/A	N/A	N/A
NCNA NuCana	2.50	Moderate Buy	$5,000.00	145,248.84% Upside
SMFL Smart for Life	0.00	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	2.00	Hold	$1.00	4,925.13% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NAVB Navidea Biopharmaceuticals	$8.13K	6.16	N/A	N/A	N/A	∞
NCNA NuCana	N/A	N/A	N/A	N/A	$324.58 per share	N/A
SMFL Smart for Life	$11.11M	0.00	N/A	N/A	($17.10) per share	0.00
SYRS Syros Pharmaceuticals	$386K	1.38	N/A	N/A	$0.79 per share	0.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NAVB Navidea Biopharmaceuticals	-$15.18M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	-$24.28M	-$646.16	N/A	N/A	N/A	N/A	-592.28%	-208.68%	N/A
SMFL Smart for Life	-$22.68M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	-$164.57M	-$3.03	N/A	N/A	N/A	N/A	-3,369.56%	-97.04%	10/29/2025 (Estimated)

Latest SMFL, NCNA, NAVB, and SYRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	NCNA NuCana	-$2.7456	-$0.16	+$2.5856	-$0.16	N/A	N/A
6/11/2025	Q3 2024	SMFL Smart for Life	N/A	-$0.94	N/A	-$0.94	N/A	$1.27 million
6/2/2025	Q1 2025	NCNA NuCana	-$2.5820	-$126.00	-$123.4180	-$0.63	N/A	N/A
5/23/2025	Q2 2024	SMFL Smart for Life	N/A	-$2.41	N/A	-$2.34	N/A	$0.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A
NCNA NuCana	N/A	1.58	1.25
SMFL Smart for Life	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NAVB Navidea Biopharmaceuticals	0.01%
NCNA NuCana	44.00%
SMFL Smart for Life	28.39%
SYRS Syros Pharmaceuticals	91.47%

Insider Ownership

Company	Insider Ownership
NAVB Navidea Biopharmaceuticals	43.68%
NCNA NuCana	31.20%
SMFL Smart for Life	31.71%
SYRS Syros Pharmaceuticals	12.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NAVB Navidea Biopharmaceuticals	10	100.08 million	56.37 million	Optionable
NCNA NuCana	30	30,000	21,000	Not Optionable
SMFL Smart for Life	110	7.09 million	4.84 million	Not Optionable
SYRS Syros Pharmaceuticals	120	26.83 million	23.54 million	Optionable

SMFL, NCNA, NAVB, and SYRS Headlines

Recent News About These Companies

Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals

April 15, 2025 | msn.com

Syros Pharmaceuticals trading resumes

March 1, 2025 | markets.businessinsider.com

Syros Pharmaceuticals Plans to Wind Down Operations

March 1, 2025 | marketwatch.com

Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock

March 1, 2025 | markets.businessinsider.com

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

February 28, 2025 | businesswire.com

Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline

January 29, 2025 | msn.com

Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?

January 18, 2025 | bovnews.comB

What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?

January 16, 2025 | bovnews.comB

SYRS’s Latest Surge: What’s Behind the Spike?

January 6, 2025 | bovnews.comB

The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again

January 2, 2025 | bovnews.comB

Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?

December 31, 2024 | bovnews.comB

Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears

December 27, 2024 | bovnews.comB

Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed

December 26, 2024 | bovnews.comB

What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?

December 14, 2024 | bovnews.comB

Syros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?

December 7, 2024 | bovnews.comB

Why Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?

December 5, 2024 | bovnews.comB

Nancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock

December 5, 2024 | insidertrades.com

Syros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. Wainwright

December 2, 2024 | bovnews.comB

Why Is Syros Pharmaceuticals Inc (SYRS) Stock Lagging Behind -84.72% from Its 50-Day SMA?

November 29, 2024 | bovnews.comB

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $36,372.51 in Stock

November 28, 2024 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMFL, NCNA, NAVB, and SYRS Company Descriptions

Navidea Biopharmaceuticals NYSE:NAVB

$0.0005 0.00 (0.00%)

As of 08/22/2025

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

NuCana NASDAQ:NCNA

$3.44 +0.13 (+3.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.39 -0.05 (-1.45%)

As of 08/22/2025 07:59 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Smart for Life NASDAQ:SMFL

$0.0033 -0.01 (-69.44%)

As of 08/22/2025 02:52 PM Eastern

Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.

Syros Pharmaceuticals NASDAQ:SYRS

$0.02 +0.02 (+1,143.75%)

As of 08/22/2025 03:18 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time